The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein]
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein]
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein]
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]
[Calcium results in increased activity of ACO2 protein] which results in increased reduction of thiazolyl blue; [Potassium deficiency results in decreased activity of ACO2 protein] which results in decreased reduction of thiazolyl blue
NQO2 protein results in increased reduction of thiazolyl blue resveratrol inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA
Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]
CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride]
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] Benzophenoneidum results in increased expression of ALDH1A1 protein
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein
[Azure B affects the cleavage of APP protein] which results in decreased secretion of APP protein modified form; Azure B results in decreased expression of and affects the cleavage of APP protein
Benzalkonium Compounds analog results in increased cleavage of CASP3 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein]
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein] Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA
Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein
Benzalkonium Compounds results in increased secretion of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein
Benzalkonium Compounds results in increased secretion of IL6 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA Benzalkonium Compounds results in increased activity of MMP9 protein
Benzalkonium Compounds analog results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein]
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein
Chlormequat results in increased expression of RNF185 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein]
Chlormequat results in increased expression of UBE2D1 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein]
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA
Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA]
Colforsin results in increased expression of ABCG2 mRNA Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]
Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form Colforsin results in increased expression of ACHE mRNA
Colforsin results in decreased expression of ACTA2 protein Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium]
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]
ADRB1 protein polymorphism affects the susceptibility to Colforsin [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] Colforsin results in increased expression of ADRB2 mRNA Colforsin results in increased phosphorylation of ADRB2 protein
[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA]
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]
Colforsin results in increased expression of ALPP mRNA [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA; Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Desipramine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]
AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein] Colforsin results in increased expression of AR protein
Colforsin results in increased expression of AREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein]
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of BCL2 mRNA; S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of BCL2 mRNA]
1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF protein] Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein
BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]
Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein]
Colforsin results in increased activity of CASP3 protein Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein] Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein]
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] Colforsin results in increased expression of CEBPA protein
Colforsin affects the localization of CFTR protein Colforsin results in increased activity of CFTR protein [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein] 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form] Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form
Colforsin results in increased secretion of CGA protein Colforsin results in increased expression of CGA protein Colforsin results in increased expression of CGA mRNA Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein] Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR1 protein affects the susceptibility to Colforsin
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR2 protein affects the susceptibility to Colforsin
Colforsin results in increased activity of CREB1 protein Colforsin results in increased expression of CREB1 mRNA; Colforsin results in increased expression of CREB1 protein modified form Colforsin results in increased phosphorylation of CREB1 protein 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]
Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein
CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone] Colforsin results in increased secretion of CRH protein [perfluorooctane sulfonic acid co-treated with Colforsin] results in increased expression of CRH mRNA
Colforsin affects the expression of CYP11A1 mRNA [Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA Colforsin results in increased expression of CYP11A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA] [Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein]
Colforsin results in increased activity of CYP11B1 protein Colforsin results in increased expression of CYP11B1 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B1 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B1 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B1 mRNA]
Colforsin results in increased expression of CYP11B2 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA]
Colforsin results in increased expression of CYP17A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]
Colforsin results in increased activity of CYP19A1 protein Colforsin results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] Colforsin results in increased expression of CYP19A1 mRNA; Colforsin results in increased expression of CYP19A1 protein
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA] Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]
Colforsin results in increased expression of CYP3A4 mRNA [S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in increased expression of CYP3A4 mRNA
Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein] Colforsin results in increased expression of DBH protein
Colforsin results in increased activity of DIO2 protein Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]]
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA]
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein]
Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein]
[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA] Colforsin results in increased expression of ERVFRD-1 mRNA; Colforsin results in increased expression of ERVFRD-1 protein Colforsin results in increased secretion of ERVFRD-1 protein
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] Colforsin results in decreased expression of ESR2 mRNA
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]
[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein]
FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]
FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]
[Dexamethasone co-treated with Colforsin] results in increased expression of G6PC1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of G6PC1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA]
Calcium promotes the reaction [Colforsin results in increased secretion of GAST protein]; Nitrendipine inhibits the reaction [Colforsin results in increased secretion of GAST protein] 2',5'-dideoxyadenosine inhibits the reaction [Colforsin results in increased secretion of GAST protein]
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; Colforsin results in increased acetylation of and results in increased activity of GCM1 protein; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein]; trichostatin A promotes the reaction [Colforsin results in increased acetylation of and results in increased activity of GCM1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of GCM1 mRNA] Colforsin results in decreased expression of GCM1 mRNA
[Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Colforsin binds to and results in increased activity of GPBAR1 protein
Colforsin results in increased phosphorylation of GRIN1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein] Colforsin results in increased expression of GRIN2B mRNA; Colforsin results in increased expression of GRIN2B protein
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
Colforsin affects the expression of HMGCR mRNA Colforsin results in increased expression of HMGCR mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HMGCR mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HMGCR mRNA; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HMGCR mRNA]
Colforsin results in increased expression of HMOX1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein] Colforsin results in increased expression of HMOX1 mRNA; Colforsin results in increased expression of HMOX1 protein
HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 protein]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 mRNA]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 protein] Colforsin results in increased expression of HSD11B2 mRNA; Colforsin results in increased expression of HSD11B2 protein
Colforsin affects the expression of HSD17B1 mRNA Colforsin results in increased expression of HSD17B1 mRNA [Colforsin co-treated with Aminoglutethimide] results in decreased expression of HSD17B1 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD17B1 mRNA; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B1 mRNA]
Colforsin affects the expression of HSD17B4 mRNA Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B4 mRNA]
Colforsin results in increased expression of HSD3B2 mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HSD3B2 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; daidzein inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
Colforsin inhibits the reaction [N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno(1,2-c)pyrazole-3-carboxamide results in increased expression of HTR2A mRNA]
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]
Colforsin results in increased expression of IGFBP1 [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of IGFBP1 mRNA
Colforsin inhibits the reaction [oxophenylarsine promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein]]; Colforsin results in increased expression of [IL12B protein binds to IL23A protein] Colforsin results in increased expression of IL12B protein
Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein]
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein]
Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]; Colforsin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin results in increased secretion of IL6 protein oxophenylarsine inhibits the reaction [Colforsin results in increased secretion of IL6 protein]
FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]
1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin results in increased secretion of INS1 protein]; Budesonide inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]; Dexamethasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Fluticasone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Hydrocortisone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Melatonin inhibits the reaction [Colforsin results in increased secretion of INS1 protein]; Probenecid promotes the reaction [Colforsin results in increased secretion of INS1 protein]
AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein] Colforsin results in increased expression of INSIG1 mRNA; Colforsin results in increased expression of INSIG1 protein
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]
AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein] Colforsin results in increased expression of KLK3 mRNA; Colforsin results in increased expression of KLK3 protein
Colforsin results in decreased expression of LEP mRNA Colforsin results in decreased secretion of LEP protein Colforsin inhibits the reaction [Caffeine results in decreased expression of LEP mRNA]
Colforsin results in increased expression of LHB protein [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]
[Colforsin co-treated with deoxynivalenol] results in increased expression of LHCGR mRNA; [Colforsin co-treated with Zearalenone] results in increased expression of LHCGR mRNA
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Colforsin results in increased secretion of LYZ protein]; [Thapsigargin co-treated with Colforsin] results in increased secretion of LYZ protein Colforsin results in decreased secretion of LYZ protein
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K1 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K1 protein]
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K2 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAP2K2 protein]
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK1 protein] 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; [Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; Colforsin promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Colforsin results in increased phosphorylation of MAPK1 protein] [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK1 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]
Colforsin results in increased phosphorylation of MAPK3 protein Colforsin results in increased activity of MAPK3 protein 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; [Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; Dieldrin promotes the reaction [[Colforsin co-treated with Rolipram co-treated with Picrotoxin] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK3 protein] [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK3 protein; alisol B promotes the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein] Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK3 protein]
Colforsin results in increased expression of MITF mRNA; Colforsin results in increased expression of MITF protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF mRNA; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF mRNA]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MITF protein]
Colforsin inhibits the reaction [Dinoprostone results in increased expression of MYH7 protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA]
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Colforsin results in increased expression of NGF mRNA
Colforsin inhibits the reaction [Dinoprostone results in increased expression of NPPA protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
Colforsin results in increased expression of NR4A1 mRNA; Colforsin results in increased expression of NR4A1 protein [Colforsin co-treated with deoxynivalenol] results in increased expression of NR4A1 mRNA; Colforsin promotes the reaction [Zearalenone results in increased expression of NR4A1 mRNA]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 protein]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 protein] NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]
666-15 compound inhibits the reaction [Colforsin results in increased expression of NR4A2 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR4A2 mRNA; Colforsin results in increased expression of NR4A2 protein
alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR5A2 mRNA
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA; U 0126 inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA]
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein] Colforsin results in increased cleavage of PARP1 protein
Colforsin results in increased expression of PCK1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of PCK1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA] Dexamethasone promotes the reaction [Colforsin results in increased expression of PCK1 mRNA]
PDK1 protein affects the susceptibility to Colforsin [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA; AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA]; beta-Naphthoflavone inhibits the reaction [Colforsin results in increased expression of PER1 mRNA]
Colforsin results in increased expression of PGF mRNA perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of PGF mRNA]
1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin results in increased expression of and results in increased activity of PNPLA6 protein]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PNPLA6 mRNA; Colforsin results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] Colforsin results in increased expression of PNPLA6 mRNA
Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]
Colforsin results in increased phosphorylation of PPP1R12A protein Capsaicin inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein]; capsazepine inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein]
Colforsin results in increased phosphorylation of PPP1R1B protein PDE1B protein affects the reaction [Colforsin results in increased phosphorylation of PPP1R1B protein]
Colforsin results in increased expression of PRDX2 mRNA S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of PRDX2 mRNA] Colforsin results in decreased expression of PRDX2 mRNA
Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein; PNPLA2 protein affects the reaction [Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein]
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] Colforsin results in increased activity of PRKACA protein
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]; [PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein]; PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein]
Colforsin inhibits the reaction [Octreotide results in decreased secretion of PRL protein]; Octreotide inhibits the reaction [Colforsin results in increased expression of PRL protein] [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]]
Colforsin promotes the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin results in increased expression of PTGS2 mRNA bifenthrin inhibits the reaction [Colforsin results in increased expression of PTGS2 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein]; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein]
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Colforsin inhibits the reaction [Morphine results in increased phosphorylation of RELA protein] RELA affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone]
Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]
Colforsin results in increased expression of REN mRNA [Sodium, Dietary deficiency results in increased susceptibility to Colforsin] which results in increased secretion of REN protein Colforsin results in increased secretion of REN protein
Colforsin results in increased expression of SDC1 mRNA [Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of SDC1 mRNA]
[Colforsin co-treated with Rolipram] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]
Colforsin results in decreased expression of SESN1 mRNA; Colforsin results in decreased expression of SESN1 protein AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]
SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA]
Valproic Acid promotes the reaction [Colforsin results in decreased expression of SLC1A5 protein] Colforsin results in decreased expression of SLC1A5 mRNA; Colforsin results in decreased expression of SLC1A5 protein
Colforsin promotes the reaction [Fructose results in increased expression of SLC2A5 mRNA]; Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA] [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein; Colforsin results in increased expression of and results in decreased degradation of SLC2A5 mRNA Colforsin results in increased expression of SLC2A5 mRNA
Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein] Colforsin results in increased expression of SLC5A5 mRNA; Colforsin results in increased expression of SLC5A5 protein
Colforsin affects the splicing of SNAP25 exon Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] Colforsin results in increased expression of SOCS3 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]
Colforsin results in increased expression of SOD2 mRNA [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] Colforsin results in increased activity of SOD2 protein
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]
[Colforsin co-treated with Diethylhexyl Phthalate] results in increased expression of STAR protein; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of STAR mRNA] [Colforsin co-treated with deoxynivalenol] results in increased expression of STAR mRNA; Colforsin affects the reaction [Zearalenone results in increased expression of STAR mRNA]; ferulic acid analog promotes the reaction [Colforsin results in increased expression of STAR mRNA]; ferulic acid analog promotes the reaction [Colforsin results in increased expression of STAR protein]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR protein] Colforsin results in increased expression of STAR mRNA; Colforsin results in increased expression of STAR protein [Atrazine co-treated with Colforsin] results in increased expression of STAR mRNA
Colforsin results in decreased expression of SULT2A1 mRNA Hexachlorocyclohexane promotes the reaction [Colforsin results in decreased expression of SULT2A1 mRNA]
Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]; HU 211 inhibits the reaction [Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]]
Colforsin inhibits the reaction [Dronabinol results in increased expression of TGFB1 protein]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased expression of TH mRNA]; bisindolylmaleimide I inhibits the reaction [Colforsin results in increased expression of TH mRNA]; HU 211 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; KT 5720 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of TH mRNA] Colforsin results in increased expression of TH protein Colforsin results in increased activity of TH protein Colforsin results in increased expression of TH mRNA; Colforsin results in increased expression of TH protein
Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of TIMP2 protein] Colforsin results in increased expression of TIMP2 protein
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]; Colforsin inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased expression of TNF mRNA]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Colforsin results in decreased expression of TNF protein
Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1] Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]; Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1]
Colforsin results in increased activity of TYR protein Colforsin results in decreased expression of TYR protein Colforsin results in increased expression of TYR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Colforsin results in increased expression of TYR protein]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TYR mRNA; [Colforsin co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Colforsin co-treated with Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] promotes the reaction [Colforsin results in increased expression of TYR protein]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein]; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TYR mRNA]; glabridin inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of TYR protein] Colforsin results in increased expression of TYR mRNA [resveratrol co-treated with Colforsin] results in decreased activity of TYR protein; [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYR mRNA]; Colforsin results in increased expression of and results in increased activity of TYR protein; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYR mRNA]
Colforsin results in increased expression of TYRP1 mRNA; Colforsin results in increased expression of TYRP1 protein [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA]; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA]
Colforsin inhibits the reaction [geniposide results in decreased expression of UCP1 mRNA]; Colforsin inhibits the reaction [geniposide results in decreased expression of UCP1 protein]
USF1 gene polymorphism promotes the reaction [Colforsin results in increased metabolism of Lipids]; USF1 protein affects the reaction [Colforsin results in increased metabolism of Lipids]
Colforsin results in increased phosphorylation of VASP protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of VASP protein]
Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of VEGFA mRNA]
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein] which results in decreased susceptibility to Cisplatin; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP mRNA; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein
Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]]
Gentian Violet promotes the reaction [TP53 protein binds to BBC3 promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]]
Gentian Violet promotes the reaction [TP53 protein binds to CDKN1A promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA]
[Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein] inhibits the reaction [STAT3 protein binds to SOX2 promoter]
[Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein] inhibits the reaction [STAT3 protein binds to SOX2 promoter]; Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein
Gentian Violet inhibits the reaction [NOX1 protein results in decreased activity of TP53 protein]; Gentian Violet promotes the reaction [TP53 protein binds to BBC3 promoter]; Gentian Violet promotes the reaction [TP53 protein binds to CDKN1A promoter]; Gentian Violet promotes the reaction [TP53 protein binds to TP53AIP1 promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA]; Gentian Violet results in increased stability of and results in increased activity of TP53 protein; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]] Gentian Violet affects the activity of TP53 protein
Donepezil results in decreased activity of ACHE protein Donepezil binds to ACHE protein Donepezil inhibits the reaction [Celecoxib results in increased activity of ACHE protein]; Donepezil inhibits the reaction [Scopolamine results in increased activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein] ALB protein affects the reaction [Donepezil results in decreased activity of ACHE protein]; Donepezil binds to and results in decreased activity of ACHE protein; Donepezil inhibits the reaction [asoxime chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]; Donepezil inhibits the reaction [Obidoxime Chloride metabolite results in decreased activity of ACHE protein]; Donepezil promotes the reaction [Obidoxime Chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]] Donepezil affects the activity of ACHE protein [Donepezil co-treated with Sodium Azide] results in increased activity of ACHE protein; AFDX 384 affects the reaction [Donepezil affects the activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Donepezil results in increased abundance of APP protein Donepezil results in decreased susceptibility to APP protein Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein] Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of APP protein]
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]]
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] Donepezil inhibits the reaction [Scopolamine results in decreased expression of BCL2 protein]
Donepezil results in increased activity of CASP3 protein Donepezil inhibits the reaction [Scopolamine results in increased activity of CASP3 protein] Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of CASP3 protein]
Donepezil inhibits the reaction [Scopolamine results in decreased activity of CAT protein]; Donepezil inhibits the reaction [Streptozocin results in decreased activity of CAT protein]
Donepezil inhibits the reaction [Scopolamine results in decreased expression of EGR1 protein] EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of EGR1 mRNA; Donepezil affects the expression of EGR1 protein
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]]
EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of ICAM1 mRNA; Donepezil affects the expression of ICAM1 protein
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL1B protein] [Sodium Azide co-treated with Donepezil] results in increased expression of IL1B protein
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL10]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL13]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]]
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL6 protein] Donepezil affects the expression of IL6 mRNA Donepezil affects the secretion of IL6 protein
Donepezil results in decreased expression of MMP9 protein Donepezil results in decreased expression of and results in decreased activity of MMP9 protein
Donepezil inhibits the reaction [Streptozocin results in increased activity of MPO protein] [Sodium Azide co-treated with Donepezil] results in increased activity of MPO protein
Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein]
Donepezil results in decreased expression of PTGS1 mRNA [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 mRNA; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 protein; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 protein; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 protein Donepezil affects the expression of PTGS1 protein
[Donepezil co-treated with Rivastigmine] results in decreased expression of PTGS2 protein; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS2 mRNA Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of PTGS2 protein] Donepezil results in decreased expression of PTGS2 mRNA; Donepezil results in decreased expression of PTGS2 protein
Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of RELA protein]
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]]
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of TNF protein] Donepezil affects the expression of TNF mRNA Donepezil affects the secretion of TNF protein [Sodium Azide co-treated with Donepezil] results in increased expression of TNF protein; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]
Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate]
Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA] Erlotinib Hydrochloride results in increased expression of ATR mRNA
AXL results in decreased susceptibility to Erlotinib Hydrochloride [amuvatinib results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein]
Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]
Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein]
Erlotinib Hydrochloride results in increased cleavage of CASP3 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein Erlotinib Hydrochloride results in increased activity of CASP3 protein Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein]
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA
Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]
Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein Erlotinib Hydrochloride affects the phosphorylation of CTNNB1 protein Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein
Erlotinib Hydrochloride results in increased expression of DDIT3 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein Erlotinib Hydrochloride results in decreased activity of EGFR protein [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] Erlotinib Hydrochloride results in decreased expression of FOXG1 protein
Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form]
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA Erlotinib Hydrochloride results in increased secretion of IL1B protein
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein
Erlotinib Hydrochloride results in increased expression of IL6 mRNA Erlotinib Hydrochloride results in increased secretion of IL6 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride results in decreased expression of MCL1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein]
[Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein Erlotinib Hydrochloride results in decreased phosphorylation of MET protein
MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]
Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein]
Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased expression of NOX4 protein
Erlotinib Hydrochloride results in increased cleavage of PARP1 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
Erlotinib Hydrochloride results in increased expression of PML protein PML protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased localization of PML protein
Erlotinib Hydrochloride results in decreased expression of PTPN9 protein PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]
Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein]
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] Erlotinib Hydrochloride results in decreased expression of SOX9 protein
Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride [Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein]
Erlotinib Hydrochloride results in increased expression of TWIST1 protein TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein] [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
Erlotinib Hydrochloride results in decreased expression of TYMS protein Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]
Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA]
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of BAX protein]
EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of BCL2 protein]
EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP3 protein]; EUK-134 inhibits the reaction [evodiamine results in increased cleavage of CASP3 protein]
EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP9 protein]; EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP9 protein]
EUK-134 affects the reaction [Vitamin K 3 results in increased expression of CDKN1A protein]; EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]
EUK-134 inhibits the reaction [Asbestos, Amosite results in increased expression of ERN1 protein]; EUK-134 inhibits the reaction [Thapsigargin results in increased expression of ERN1 protein]
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [Zinc Sulfate inhibits the reaction [EUK-134 results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]]
[Acetylcysteine co-treated with EUK-134] promotes the reaction [[Zinc Sulfate co-treated with Paraquat] results in increased activity of GSTA4 protein]; [EUK-134 co-treated with Acetylcysteine] promotes the reaction [Paraquat results in increased activity of GSTA4 protein]; [EUK-134 co-treated with Acetylcysteine] promotes the reaction [Zinc Sulfate results in increased activity of GSTA4 protein]
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of HES1 protein]
EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of MDM2 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of MDM2 protein]
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased activity of MPO protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Paraquat results in increased activity of MPO protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased activity of MPO protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]]
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT1A protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]]
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT2A protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]]
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of TP53 protein]
[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA; NPC1 protein affects the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein]; UVI 3003 inhibits the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein] Fingolimod Hydrochloride results in increased expression of ABCA1 mRNA; Fingolimod Hydrochloride results in increased expression of ABCA1 protein
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 protein]
Fingolimod Hydrochloride promotes the reaction [Mercuric Chloride results in increased expression of ADM mRNA]; Fingolimod Hydrochloride promotes the reaction [Mercuric Chloride results in increased expression of ADM protein]
Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pifithrin inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]
BECN1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of BECN1 protein]; Fingolimod Hydrochloride results in increased expression of and results in increased cleavage of BECN1 protein
3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP3 protein] Fingolimod Hydrochloride results in increased activity of CASP3 protein
Fingolimod Hydrochloride results in increased cleavage of CASP8 protein SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP8 protein]
3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid inhibits the reaction [Fingolimod Hydrochloride results in increased expression of CCL2 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of CCL2 protein CCL2 results in increased susceptibility to Fingolimod Hydrochloride
Fingolimod Hydrochloride results in decreased expression of CCND1 mRNA Estradiol inhibits the reaction [Fingolimod Hydrochloride results in decreased expression of CCND1 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Estradiol results in decreased expression of CCND1 mRNA]
Fingolimod Hydrochloride inhibits the reaction [Estradiol results in increased expression of CXCR4 mRNA] Fingolimod Hydrochloride results in decreased expression of CXCR4 mRNA
Fingolimod Hydrochloride inhibits the reaction [Estradiol results in increased expression of ESR2 protein] Fingolimod Hydrochloride results in decreased expression of ESR2 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of FAS mRNA
Fingolimod Hydrochloride metabolite binds to HDAC1 protein Fingolimod Hydrochloride metabolite inhibits the reaction [S1PR1 protein binds to HDAC1 protein]; SPHK2 protein promotes the reaction [Fingolimod Hydrochloride metabolite binds to HDAC1 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in decreased expression of and results in decreased secretion of IL4 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of IL6 protein; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of IL6 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of MAP3K5 mRNA
Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 mRNA]; Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 protein]
NPC1 protein affects the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein] Fingolimod Hydrochloride results in increased expression of NPC1 protein
3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; BECN1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pifithrin inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in decreased expression of PPP2CA protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of PPP2CA mRNA
Fingolimod Hydrochloride results in increased expression of RIPK3 protein RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]
Fingolimod Hydrochloride inhibits the reaction [SPHK2 protein results in increased expression of S1PR1 protein]; Fingolimod Hydrochloride metabolite inhibits the reaction [S1PR1 protein binds to HDAC1 protein] Fingolimod Hydrochloride analog results in decreased activity of S1PR1 protein Fingolimod Hydrochloride results in decreased expression of S1PR1 protein [3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid results in decreased activity of S1PR1 protein] which results in decreased susceptibility to Fingolimod Hydrochloride
Fingolimod Hydrochloride inhibits the reaction [SPHK2 protein results in increased expression of S1PR1 protein]; SPHK2 protein promotes the reaction [Fingolimod Hydrochloride metabolite binds to HDAC1 protein] SPHK2 results in increased susceptibility to Fingolimod Hydrochloride SPHK2 protein results in increased phosphorylation of Fingolimod Hydrochloride
Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP8 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein] Fingolimod Hydrochloride results in decreased expression of SQSTM1 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of STAT1 protein modified form
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride] results in increased expression of and results in increased secretion of TNF protein; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of TNF protein]
Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLC mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of GCLC mRNA]
Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP protein]
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of HMOX1 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of HMOX1 mRNA] Methylene Blue results in increased expression of HMOX1 protein
Methylene Blue inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] Methylene Blue results in decreased activity of MAOB protein
Methylene Blue results in decreased expression of MAPT protein [Methylene Blue co-treated with MAPT protein mutant form] affects the localization of NFE2L2 protein; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLC mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLM mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of HMOX1 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NFE2L2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NQO1 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of PRDX6 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXN2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXNRD2 mRNA; Methylene Blue affects the reaction [MAPT protein mutant form affects the expression of TXNRD1 mRNA]; Methylene Blue affects the reaction [MAPT protein mutant form results in increased expression of TXN mRNA]; Methylene Blue co-treated with [MAPT protein mutant form results in increased expression of NOS2 mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP protein] Methylene Blue results in decreased phosphorylation of MAPT protein modified form Methylene Blue results in increased expression of MAPT mRNA
Methylene Blue inhibits the reaction [Paraquat results in increased expression of MPO protein]; Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]
[Methylene Blue co-treated with MAPT protein mutant form] affects the localization of NFE2L2 protein; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NFE2L2 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of GCLC mRNA]; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of HMOX1 mRNA]; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of NQO1 mRNA] Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of NFE2L2 mRNA]
Methylene Blue co-treated with [MAPT protein mutant form results in increased expression of NOS2 mRNA] Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of NOS2 protein]
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NQO1 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of NQO1 mRNA]
ABCB1 protein results in increased export of mitotracker green FM LCL161 inhibits the reaction [ABCB1 protein results in increased export of mitotracker green FM]
[N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride binds to and results in decreased activity of SIGMAR1 protein] inhibits the reaction [1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy-2(1H)-quinolinone results in increased secretion of Acetylcholine]
[1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine binds to and results in decreased activity of HTR1A protein] which results in decreased susceptibility to Serotonin [1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine binds to and results in decreased activity of HTR1A protein] which results in decreased susceptibility to Methamphetamine
CSF2 protein affects the susceptibility to [Nitroblue Tetrazolium co-treated with methyl 2,5-dihydroxycinnamate]; CSF2 protein affects the susceptibility to [Nitroblue Tetrazolium co-treated with psi-tectorigenin]; CSF2 protein affects the susceptibility to [Nitroblue Tetrazolium co-treated with Staurosporine] CSF2 protein affects the susceptibility to Nitroblue Tetrazolium
[Cerulenin results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine
Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]
Phosphorylcholine analog results in increased expression of TIMP1 mRNA Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of BDNF protein]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased phosphorylation of CREB1 protein]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of MIR22 mRNA]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased sumoylation of NFKBIA protein]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of SIRT1 protein]
Prasugrel Hydrochloride inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of UBE2I protein]
Quinapril results in decreased activity of AGT protein Quinapril inhibits the reaction [Isoproterenol results in increased expression of AGT protein]; Quinapril promotes the reaction [Isoproterenol results in increased expression of AGT protein]
[Tacrolimus co-treated with Quinapril] results in decreased expression of IL6 protein; [Tacrolimus co-treated with Quinapril] results in increased expression of IL6 protein
Quinapril results in increased expression of NPPA mRNA; Quinapril results in increased expression of NPPA protein Quinapril results in increased secretion of NPPA protein
Quinapril inhibits the reaction [Folic Acid results in increased expression of PTHLH mRNA]; Quinapril inhibits the reaction [Folic Acid results in increased expression of PTHLH protein]
Quinapril promotes the reaction [Isoproterenol results in increased expression of REN protein] Quinapril results in increased expression of REN protein
3-methylquercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 3-methylquercetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; 5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 5,7-dimethoxyflavone inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; 5-hydroxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 5-methoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 5-oxo-hexahydroquinoline analog inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]; [zosuquidar trihydrochloride results in decreased activity of ABCB1 protein] which results in decreased export of Rhodamine 123; abemaciclib inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]; baicalein inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; baicalein promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; betulin inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]; biochanin A inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; biochanin A promotes the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; CEP 33779 inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]; daidzein inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; flavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; formononetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Genistein promotes the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; glycitein promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; isovitexin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; kaempferol inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; myricetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; naringenin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; naringin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Quercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; Quercetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; quercitrin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Rutin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; tangeretin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; tangeretin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; taxifolin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123] [P-glycoprotein inducer and activator TX5 results in increased activity of ABCB1 protein] which results in increased export of Rhodamine 123; [Verapamil results in decreased activity of ABCB1 protein] inhibits the reaction [P-glycoprotein inducer and activator TX5 results in increased export of Rhodamine 123]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased expression of ATG9A protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased expression of BECN1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased expression of DAPK2 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Doxorubicin results in increased expression of DDIT3 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Doxorubicin results in increased expression of HSPA5 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Aflatoxin B1 results in increased phosphorylation of MAPK1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Aflatoxin B1 results in increased phosphorylation of MAPK3 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Oxygen deficiency results in increased phosphorylation of MYL9 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Lipopolysaccharides affects the localization of NFATC1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [fluoranthene results in increased expression of NOS3 protein]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [fluorene results in increased expression of NOS3 protein]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [naphthalene results in increased expression of NOS3 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased expression of ORAI1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [[Particulate Matter co-treated with Methylene Chloride] results in increased expression of PTGS2 mRNA]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in decreased expression of SQSTM1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased expression of STIM1 protein]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [[Phenylephrine results in increased expression of TRPC3 protein] which results in increased transport of Calcium]
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Acetylcholine promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole promotes the reaction [Propofol results in decreased expression of TRPC6 protein] 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole results in decreased activity of TRPC6 protein
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole promotes the reaction [2,3',4,4',5-pentachlorobiphenyl results in decreased expression of TUBB3 protein]
Thiamine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]]; Thiamine inhibits the reaction [Glycerol results in increased secretion of CKM protein]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
[Thiamine deficiency results in increased expression of PTGS2 mRNA] which results in increased expression of Dinoprostone; Thiamine deficiency results in increased expression of PTGS2 mRNA
SLC19A2 protein results in increased uptake of Thiamine [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A2 protein] which results in decreased uptake of Thiamine Thiamine deficiency results in increased expression of SLC19A2 mRNA; Thiamine deficiency results in increased expression of SLC19A2 protein
Thiamine deficiency results in increased expression of SLC19A3 mRNA; Thiamine deficiency results in increased expression of SLC19A3 protein Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Chloroquine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Metformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Phenformin inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]; Verapamil inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of SLC19A3 protein] which results in decreased uptake of Thiamine
[Dichlorvos results in increased phosphorylation of ACHE protein] inhibits the reaction [thioflavin T binds to ACHE protein]; [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased phosphorylation of ACHE protein] inhibits the reaction [thioflavin T binds to ACHE protein]; [thioflavin T binds to ACHE protein] inhibits the reaction [ACHE protein results in increased hydrolysis of Acetylthiocholine]; thioflavin T binds to and results in decreased activity of ACHE protein; thioflavin T inhibits the reaction [hopeahainol A binds to ACHE protein]
SLCO1A2 protein results in increased metabolism of trospium chloride trospium chloride results in decreased activity of SLCO1A2 protein; trospium chloride results in decreased activity of SLCO1A2 protein alternative form
CYP2C8 protein results in decreased degradation of vanoxerine [Quercetin results in decreased activity of CYP2C8 protein] which results in decreased degradation of vanoxerine
CYP2E1 protein results in decreased degradation of vanoxerine [Chlorzoxazone results in decreased activity of CYP2E1 protein] which results in decreased degradation of vanoxerine
[Ketoconazole results in decreased activity of CYP3A4 protein] which results in decreased degradation of vanoxerine; [Quercetin results in decreased activity of CYP3A4 protein] which results in decreased degradation of vanoxerine CYP3A4 protein results in decreased degradation of vanoxerine
vanoxerine binds to SLC6A3 protein vanoxerine results in decreased activity of SLC6A3 protein vanoxerine affects the reaction [Cocaine affects the expression of SLC6A3 protein] SLC6A3 protein affects the susceptibility to vanoxerine vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] SLC6A3 gene mutant form results in decreased susceptibility to vanoxerine [vanoxerine results in decreased activity of SLC6A3 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; vanoxerine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein]
Vecuronium Bromide results in increased expression of HSD11B2 mRNA; Vecuronium Bromide results in increased expression of HSD11B2 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of ACTA2 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of ACTA2 protein]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of BAX protein]]; Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of BAX protein]
Venlafaxine Hydrochloride results in decreased expression of BCL2 mRNA Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BECN1 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BECN1 protein]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of CASP3 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of CASP3 protein]
Nitric Oxide promotes the reaction [Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]]; Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; Venlafaxine Hydrochloride inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] Venlafaxine Hydrochloride results in decreased activity of CYP17A1 protein
CYP2C19 gene polymorphism affects the methylation of Venlafaxine Hydrochloride CYP2C19 protein results in decreased methylation of Venlafaxine Hydrochloride
CYP2D6 gene mutant form affects the metabolism of Venlafaxine Hydrochloride; CYP2D6 gene polymorphism affects the metabolism of Venlafaxine Hydrochloride CYP2D6 gene polymorphism affects the methylation of Venlafaxine Hydrochloride CYP2D6 protein affects the susceptibility to Venlafaxine Hydrochloride CYP2D6 protein results in decreased methylation of Venlafaxine Hydrochloride CYP2D6 protein results in increased metabolism of Venlafaxine Hydrochloride Venlafaxine Hydrochloride results in decreased activity of CYP2D6 protein
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of HDAC6 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of HDAC6 protein]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of HDAC6 protein]
Venlafaxine Hydrochloride affects the activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Venlafaxine Hydrochloride affects the activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased lipidation of MAP1LC3B protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased lipidation of MAP1LC3B protein]
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of PRKN protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of PRKN protein]
Venlafaxine Hydrochloride results in decreased expression of SQSTM1 mRNA Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of SQSTM1 protein]]; Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of SQSTM1 protein]
browse the term
